about
High-pressure liquid chromatography analysis and single-dose disposition of tobramycin in human volunteers.The effect of assay methods on plasma levels and pharmacokinetics of theophylline: HPLC and EIAAccumulation of midazolam after repeated dosage in patients receiving mechanical ventilation in an intensive care unit.Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates.Total extraction of aminoglycosides from guinea pig and bullfrog tissues with sodium hydroxide or trichloroacetic acid.Pharmacokinetics of amikacin in serum and in tissue contiguous with pressure sores in humans with spinal cord injuryNew sodium hydroxide digestion method for measurement of renal tobramycin concentrationsRenal cortical kinetics of gentamicin after implantation of gentamicin-polymethylmethacrylate beads in ratsAmikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients.Predicted tissue accumulation of netilmicin in patients.Accumulation pharmacokinetics of tobramycin.Isepamicin disposition in subjects with various degrees of renal function.Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning.Drug level monitoring in paediatric practice.Treatment of gram-negative infections in patients with renal impairment: new alternatives to aminoglycosides.Therapeutic initiatives for the avoidance of aminoglycoside toxicity.Comparison of netilmicin and gentamicin pharmacokinetics in humans.Pharmacokinetic properties of netilmicin in newborn infants.Gentamicin pharmacokinetics in kwashiorkor.Specificity of renal tubular damage criteria for aminoglycoside nephrotoxicity in critically ill patients.New pharmacokinetic methods. III. Two simple test for "deep pool effect".Reappraisal of guidelines for pharmacokinetic monitoring of aminoglycosides.Effect of nonsteroidal anti-inflammatory drugs with varying extent of COX-2-COX-1 selectivity on urinary sodium and potassium excretion in the rat.Parents and mentors may be gone but they are never forgotten.A microcomputer program for tobramycin consult services, based on the two-compartment pharmacokinetic model.
P2860
Q33727108-031891F6-202F-4972-A60B-5169F8810B44Q34517559-A9A7D70E-257D-46D3-AF72-836BC5C9FA62Q34552609-A955FACF-C0AA-43DF-A77C-545E5BC2F472Q34570930-24447E99-94AA-4E69-AF38-960D5CD7980CQ35325563-1FE7972F-20AC-4C78-8EA3-BCB5013C8D54Q35565358-FB47D400-F5A9-4B09-B856-52557355A930Q35652481-2012778A-FE6C-4E82-A31A-BD2B69536AF7Q35652658-2D64D48A-BFEA-49E2-B10E-A445EAC10FDDQ35668521-DD8B9FB7-6D38-44A6-96AF-E1066AFF6940Q35672495-D07AB409-A3C4-4E8B-A2C5-6FA11AB50BA5Q36468777-22AFF864-C227-4E17-B20D-23D1BEAD2D71Q36757182-767F442C-EE1F-4BC8-B7D9-650046EEBEA8Q36863642-E26FDFEE-73F1-44A7-9D91-0C9D1F08C15CQ38914642-0850DE9B-4846-424B-96B8-8436EAB40C59Q39558431-5BD03D83-A0A5-46D1-8BE1-93747A0E2E74Q39818301-22808EDC-DFEC-46B7-A7B1-75F5D9F720B0Q40281418-1424BE6E-A785-43F0-9A61-197849B63D38Q40619982-2E4246D2-CC64-43CF-8E5C-9BCF8B8DB246Q41998380-73512E60-7784-4FCE-8227-98CA39CA9E07Q42254063-F12BEB69-6FB6-40C0-B1E2-23070A12F325Q43718863-7E22DF97-3D39-460F-AE6A-85C3C7EC91B5Q45006893-CC561EED-C52E-48E5-BE20-9C90ABFDFA15Q46368581-7B520506-81CC-4ADB-A7C9-D5374781CB3EQ48538639-B235A8E2-9B9E-49CF-ABAB-9967B13569C5Q48662614-4446C417-1D9C-4620-9133-B0B09879ECA0
P2860
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
1977年论文
@zh
1977年论文
@zh-cn
name
Tissue persistence of gentamicin in man.
@en
type
label
Tissue persistence of gentamicin in man.
@en
prefLabel
Tissue persistence of gentamicin in man.
@en
P2093
P1476
Tissue persistence of gentamicin in man.
@en
P2093
P304
P356
10.1001/JAMA.1977.03280040047019
P407
P577
1977-07-01T00:00:00Z